NEW YORK, July 9 - PerkinElmer will develop and sell fluorescence-based SNP-diagnostic assays gleaned from genotyping technology owned by Orchid Bioscience, the companies said today.
By taking this step, PerkinElmer cashes in an option granted by Orchid to obtain exclusive rights to its SNP-IT technology in fluorescence polarization-based reagent kits.
That agreement, struck in December 2000, gave PerkinElmer exclusive rights to sell to the products market tools based on the Orchid technology. The latest option allows PerkinElmer to concentrate on the molecular-diagnostics market, the firms said.
Click here for more information.